Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Akebia Therapeutics, Amarin, AstraZeneca, and Pfizer-Merck Alliance.

Community Practice Connections™: 3rd Annual New York Cardio-Endo-Renal Collaborative (NY CERC)

Release Date: December 3, 2019
Expiration Date: December 3, 2020
Media: Internet - based

Activity Overview

The increasing prevalence of cardiometabolic risk continues to be a major challenge for health care providers in the United States because they are currently not managed adequately in clinical practice. With the increase in the number of patients presenting with obesity, diabetes, and hypertension, there has been a parallel rise in the incidence and prevalence of cardiometabolic complications. Cardiometabolic risk incorporates a collection of risk factors that predispose individuals to cardiovascular disease. These risk factors involve multiple pathways and physiologic systems and point to a need for a comprehensive management approach. As a number of cardiometabolic risk factors begin to emerge, patients begin to develop additional subclinical conditions that are discovered only when evaluating the entire constellation of risk factors, thereby enabling clinicians to recommend optimal treatment to prevent cardiovascular and metabolic morbidities.

Benefits of Participating

  • Gain insights into importance of screening and early detection of cardiometabolic risk factors for early efficacious management to prevent irreversible cardiovascular damage
  • Improve competence regarding the integration of novel and newly approved therapies in the management of cardiovascular, renal, and metabolic diseases
  • Increase awareness of strategies for overcoming barriers to multidisciplinary care of patients with cardiac, endocrine, and renal disease

Acknowledgement of Commercial Support

This activity is supported by educational grants from Akebia Therapeutics, Amarin, AstraZeneca, and Pfizer-Merck Alliance.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward cardiologists, endocrinologists, specialty nurse practitioners, specialty physician assistants, certified diabetes educators, other specialty allied health professionals, nephrologists, and other health care professionals (HCPs).

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Discuss clinical strategies for evaluation and diagnosis of patients presenting with cardiac, endocrine, and renal disease.
  • Evaluate the rationale behind current and emerging testing used in the stratification of cardiometabolic risk in order to optimize the use of current and emerging agents or therapeutic strategies.
  • Recognize and devise strategies to manage treatment-related adverse events and side effects in the care of patients with cardiac, endocrine, and renal disease.
  • Discern the potential clinical impact of recent clinical trial data on management of cardiac, endocrine, and renal disease.
  • Identify current strategies and recent advancements in the prevention of cardiometabolic disorders.
  • Assess barriers to care of patients with cardiac, endocrine, and renal disease.
  • Employ strategies for patient counseling to improve education, preventive practices, adherence, and self-management.

Faculty, Staff, and Planners’ Disclosures


Stephen Brunton
Stephen Brunton, MD, FAAFP
Executive Director
Primary Care Metabolic Group
Murrieta, CA
Associate Clinical Professor
Department of Family Medicine
Touro University
Vallejo, CA

Disclosures: Consultant: Advisory Board for Abbott Diabetes, Acadia Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Janssen, Merck, Mylan, Novo Nordisk, Xeris Pharmaceuticals; Speaker Bureau: AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk.

Keith C. Ferdinand
Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine
Tulane University School of Medicine
New Orleans, LA

Disclosures: Consultant: Amgen, Sanofi, Boehringer Ingelheim, Janssen, Quantum Genomics.

James Underberg
James Underberg, MD, MS, FACPM, FACP, FNLA
Immediate Past President of the National Lipid Association
Clinical Assistant Professor of Medicine
New York University School of Medicine
New York, NY

Disclosures: Grant Research Support: Aegerion Pharmaceuticals, Pfizer; Consultant: Amgen, Amarin Corporation; Speakers Bureau: Amgen, Amarin Corporation, Akcea Therapeutics, Alexion Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals; Other: Advisory Boards: Amgen, Sanofi, Regeneron Pharmaceuticals, Akcea Therapeutics, Aegerion Pharmaceuticals, Alexion Pharmaceuticals, Ambry Genetics.

Deepak L. Bhatt
Executive Director of Interventional Cardiovascular
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Amarin Corporation, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood Pharmaceuticals, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi-Aventis, The Medicines Company.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By